Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

Quisette Janssen; Jacob L. van Dam; Marc G. H. Besselink; Marjolein Y. V. Homs; Geertjan van Tienhoven; Johanna W. Wilmink; Bas Groot Koerkamp

doi:10.1200/JCO.2021.39.15_suppl.TPS4171

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

Quisette Janssen
, Jacob L. van Dam
, Marc G. H. Besselink
, Marjolein Y. V. Homs
, Geertjan van Tienhoven
, Johanna W. Wilmink
, Bas Groot Koerkamp

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

2 Citations (Web of Science)

Original language	English
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	39
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4171
Publication status	Published - 20 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1200/JCO.2021.39.15_suppl.TPS4171

Cite this

Janssen, Q., van Dam, J. L., Besselink, M. G. H., Homs, M. Y. V., van Tienhoven, G., Wilmink, J. W., & Koerkamp, B. G. (2021). Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial. Journal of Clinical Oncology, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4171

@article{0b682519eea4434a81dee4f103fbdf01,

title = "Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.",

author = "Quisette Janssen and \{van Dam\}, \{Jacob L.\} and Besselink, \{Marc G. H.\} and Homs, \{Marjolein Y. V.\} and \{van Tienhoven\}, Geertjan and Wilmink, \{Johanna W.\} and Koerkamp, \{Bas Groot\}",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15\_suppl.TPS4171",

language = "English",

volume = "39",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "15",

}

Janssen, Q , van Dam, JL, Besselink, MGH, Homs, MYV, van Tienhoven, G, Wilmink, JW & Koerkamp, BG 2021, 'Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.', Journal of Clinical Oncology, vol. 39, no. 15. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4171

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial. / Janssen, Quisette ; van Dam, Jacob L.; Besselink, Marc G. H. et al.
In: Journal of Clinical Oncology, Vol. 39, No. 15, 20.05.2021.

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

TY - JOUR

T1 - Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2)

T2 - A nationwide multicenter randomized controlled trial.

AU - Janssen, Quisette

AU - van Dam, Jacob L.

AU - Besselink, Marc G. H.

AU - Homs, Marjolein Y. V.

AU - van Tienhoven, Geertjan

AU - Wilmink, Johanna W.

AU - Koerkamp, Bas Groot

PY - 2021/5/20

Y1 - 2021/5/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000708120306273&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2021.39.15_suppl.TPS4171

DO - 10.1200/JCO.2021.39.15_suppl.TPS4171

M3 - Meeting Abstract

SN - 0732-183X

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Janssen Q , van Dam JL, Besselink MGH, Homs MYV, van Tienhoven G, Wilmink JW et al. Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial. Journal of Clinical Oncology. 2021 May 20;39(15). doi: 10.1200/JCO.2021.39.15_suppl.TPS4171

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

UN SDGs

Access to Document

Other files and links

Cite this